The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL)

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Rego, Eduardo M ^a   Kim, Haesook T ^b   Ruiz Argüelles, Guillermo J ^c   Uriarte, Maria del Rosario ^d   Jacomo, Rafael H ^a   Gutiérrez Aguirre, Homero ^e   Melo, Raul A M ^f   Bittencourt, Rosane ^g   Pasquini, Ricardo ^h   Pagnano, Katia ⁱ   Fagundes, Evandro M ^j   Chauffaille, Maria de Lourdes ^k   Chiattone, Carlos ^l   Martinez, Lem ^d   Meillón, Luis A ^m   Gómez Almaguer, David ^e   Kwaan, Hau ⁿ   Garcés Eisele, Javier ^c   Gallagher, Robert ^o   Niemeyer, Charlotte M ^p   Lowenberg, Bob ^q   Ribeiro, Raul ^r   LoCoco, Francesco ^s   Sanz, Miguel A ^t   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Clinica Ruiz   (Mexico)

^d Asociacion Espanola Primera de Socorros Mutuos   (Uruguay)

^e HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^f HEMOPE   (Brazil)

^g FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ UNIVERSITY OF CAMPINAS   (Brazil)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^m INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o ALBERT EINSTEIN CANCER CENTER   (United States)

^p UNIVERSITY OF FREIBURG   (Germany)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r St Jude Children's Rsch Hosp   (United States)

^s UNIVERSITY OF ROME TOR VERGATA   (Italy)

^t HOSPITAL UNIVERSITARIO LA FE   (Spain)

more..

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Developing countries; Leukemia

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; IDARUBICIN; RETINOIC ACID;

AGE DISTRIBUTION; ARTICLE; BONE MARROW BIOPSY; BRAZIL; CLINICAL PROTOCOL; DEVELOPING COUNTRY; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; GENETIC ANALYSIS; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HUMAN; LEUKEMIA REMISSION; MEDICAL EDUCATION; MEXICO; MONOTHERAPY; MORTALITY; OUTCOME OF EDUCATION; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SOCIAL NETWORK; TREATMENT OUTCOME; URUGUAY;

ANTINEOPLASTIC AGENTS; BONE MARROW; BRAZIL; COOPERATIVE BEHAVIOR; DAUNORUBICIN; DEVELOPING COUNTRIES; DISEASE-FREE SURVIVAL; EDUCATION, MEDICAL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEXICO; REMISSION INDUCTION; TREATMENT OUTCOME; TRETINOIN; URUGUAY;

EID: 84859768294     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155376     Document Type: Article

References (20)

1. Rego EM, Pandolfi PP. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol. 2001;38:54-70.
2. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood.2000;96:1297-308.
3. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;87:308-13.
4. Jacomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92:1431-2.
5. Melo RA, de Vasconcellos JF, Melo FC, Machado CG, Lacerda TM, Souto FR. PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. Clin Lab Haematol. 2006;28:126-9.
6. Ruiz-Arguelles GJ. Promyelocytic leukemia in Mexican mestizos. Blood. 1997;89:348-9.
7. de Salvo L, Weir Medina J, Gomez Sanchez O, de Baena ES, de Ramos BU, Guevara J, et al. [Acute promyelocytic leukemia in the west of Venezuela]. Sangre (Barc). 1989;34:329-31. Spanish.
8. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996;88:377.
9. Mendes WL, Coser VM, Ramos G, Pereira W, Lopes LF, de Oliveira MS. The apparent excess of acute promyelocytic leukemia in infant acute leukemias in Brazil. Haematologica. 2004;89:ELT16.
10. Pulsoni A, Stazi A, Cotichini R, Allione B, Cerri R, di Bona E, et al. Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative Group. Eur J Haematol. 1998;61:327-32.
11. Moorman AV, Roman E, Cartwright RA, Morgan GJ. Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK. Clin Lab Haematol. 2002;24:263-5.
12. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128-34.
13. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-91.
14. Sanz MA, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112:3130-4.
15. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-53.
16. Avvisati G, LoCoco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood. 1996;88:1390-8.
17. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 2006:162-8.
18. Sanz MA, Montesinos P, Rayon C, Vellenga E, Rayón C, de la Serna J, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137-46.
19. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997;90:4046-53.
20. Rego EM, Kim HT, Ruiz-Argüelles GJ, del Rosario Uriarte M, Jacomo RH, Gutiérrez-Aguirre H, et al. The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Blood. 2009;114:116.